Pfizer CFO to depart; GSK wins approval for UTI drug

Pfizer CFO exits; GSK wins FDA nod for oral UTI drug; Apellis trial paused; plus Mersana ADC dropped, TORL ADC data, Corcept resubmission, Verastem pancreatic update, Legend offering, COUR Series B and two program cuts, cAMPfield $180M debut and LabGenius-LG Chem AI pact. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and…

ENDPOINTS · 2026-06-18

Plus news about Apellis Pharmaceuticals, Servier, TORL BioTherapeutics, Verastem, Corcept Therapeutics, Legend Biotech, COUR Pharmaceuticals, cAMPfield Therapeutics and LabGenius Therapeutics. 👋 Pfizer’s CFO will depart in August: Dave Denton will leave ...

Source: Endpoints News